"Global & USA Cancer Immunotherapy Market Analysis to 2020
reveals that the cancer immunotherapy space will be a significant revenue generator (excess of $80 billion) for the biopharmaceutical industry by 2020. The market has been supported by the approval of Bristol-Myers' Yervoy drug for melanoma, BMS's Opdivo and Merck's Keytruda.
Within the cancer therapeutics space, which today is worth over $100 billion globally, immunotherapeutic drugs have gained worldwide acceptance. This is because they are targeted therapeutics that have high specificity for cancer cells. Today, cancer immunotherapy drugs have captured nearly 50% of the overall oncology drugs market, generating about $54 billion in 2016 alone and are forecast to surpass $100 billion in 2022.
Over the next decade, immunotherapies will be the backbone of cancer treatments in 60% of cancer types. It is forecast that by 2020, Avastin, Nivolumab, Revlimid, Rituxan and Xtandi will be the top five cancer drugs. A single drug, Bristol-Myers Squibb's Yervoy, for example has earned revenues of about $960 million in 2013 and it is expected to have a market value of $1,775.2 million in 2020. Industry Experts have predicted that Keytruda and Opdivo will generate sales revenues of $2.9 billion and $4.3 billion respectively in 2019.
The CAR-T industry is addressing unmet needs in specific relapsed cancers, however does early clinical trial data support a blockbuster status for this upcoming therapy? Some patients do indeed show long term activity and high remission rates, but there is a large proportion of patients with toxicities such as cytokine release syndrome and neurotoxicity. The main players within the CAR-T market are Juno Therapeutics, Kite Pharma, Novartis and Cellectis. The market is moving ahead, backed by years of R&D, from both academia and industry, investors capitol and small clinical studies.
The interest on ADCs can be seen with the recent approvals of Adcetris (brentuximab vedotin) and Kadcyla (ado-trastuzumab emtansine). Currently, More than 15 companies are developing 30 different ADCs targeting both hematologic malignancies and solid tumors. ADCs represent a novel class of therapeutic agents, gaining increasing attention from both large and small pharmaceutical companies.
As the ADCs carry a chemotherapy drug, they are believed to be more efficient and effective in the treatment of a disease. Due to shrinking pipelines and increasing pressure from patent expirations, big pharmaco' recognized the vaccine market as a potential resource for investors. Cancer vaccines have been found to earn a higher profit than the generic drugs, owing to the nature of the disease and the urgency in the demand for these vaccines. The global market for cancer vaccines was worth about $4.4 billion and it is likely to reach $8.4 billion in 2020.
Immunotherapy is a proven powerful tool, either as a monotherapy or as a combination therapy with chemotherapy or radiation. For patients with metastatic skin cancer or kidney cancer, immunotherapy has been found to be more effective than the conventional options, with the possibility of even a complete cure. Today, cancer immunotherapy drugs have captured nearly 50% of the overall oncology drugs market, generating about $41.0 billion in 2014 alone.
Key Questions Answered in this Report
What is the global market for cancer immunotherapeutics by product class such as MAbs, vaccines and non-specific immunotherapies, through 2022?
What is the global market for cancer immunotherapeutics by geography, through 2022?
What is the global market for cancer immunotherapeutics by indication, through 2022?
What is the global market for MAbs by type such as naked MAbs and ADCs, through 2022?
What are the market values for Herceptin, Avastin, Erbitux, Yervoy, Mabthera, Adectris, and Keytruda?
What is the global market for cancer vaccines?
What is the global market for cytokines in cancer immunotherapy?
The projected market values for Nivolumab, Tecentriq, DCVax-L, Imfinzi?
What immunotherapies were approved between 1986 and 2017?
What monoclonal antibodies (MAbs) were approved by the FDA to treat different types of cancers?
What are naked MAbs and how many of them have been approved by the FDA?
What are antibody-drug conjugates (ADCs) and how many of them are available in the market?
What are the common cytotoxic wareheads used in ADCs?
What are the important clinical assets in ADCs?
How many bispecific MAbs are in late-stage development?
What are the common side effects of MAbs in cancer immunotherapy?
What are cancer vaccines and how many of them have been licensed to be marketed?
How many cytokines have been approved for being used in cancer immunotherapy?
What are the major checkpoint inhibitors in clinical development?
What is the current status of anti-PD-1 drugs, dentritic cell therapies, T-cell therapies and cancer vaccines?
What are the most valuable R&D projects in cancer immunotherapy and what would be their approximate sales revenues in 2022?
Number of melanoma drugs approved between 1998 and 2017?
Number of lung cancer drugs approved between 1998 and 2017?
Number of brain cancer drugs approved between 1998 and 2017?
What is CAR T Therapy?
What are the main challenges associated with CAR T therapy?
What is the status of CAR T therapeutic approval?
What are the current regulations for immunotherapies in USA, Europe & Japan?
What are the main manufacturing steps in CAR T therapy?
What challenges lie ahead for CAR T production?
Key Topics Covered: 1.0 Executive Summary 1.1 Objectives of Report 1.2 Key Questions Answered in this Report 1.3 Data Sources and Methodology
2.0 Cancer Immunotherapy: An Overview 2.1 Human Immune System 2.2 Types of Cancer Immunotherapy 2.3 Monoclonal Antibodies (Mabs) to Treat Cancer 2.4 Types of Monoclonal Antibodies (MAbs) 2.5 Cancer Vaccines 2.6 Non-Specific Cancer Immunotherapies and Adjuvants 2.7 New Frontiers in Cancer Immunotherapy Research 2.8 Cancer Immunotherapy: Timeline of Progress
3.0 Current Status of Cancer Immunotherapy: An Overview 3.1 Programmed Death (PD-1) Inhibitors 3.2 Keytruda (Pembrolizumab, MK-3475) 3.3 Tecentriq from Roche 3.4 Pidilizumab from CureTech 3.5 An Overview of Anti-PD-1 Clinical Development 3.6 Studies with Yervoy (Ipilimumab) 3.7 Studies with Tremelimumab 3.8 KAHR-102 3.9 TIM3 Antibody 3.10 BMS-989016 3.11 ImmuTune IMP701 and ImmuFact IMP321 3.12 Dendritic Cell Therapies 3.13 Chimeric Antigen Receptor T-Cells (CAR-T) Therapies 3.14 Cancer Vaccines 3.15 Miscellaneous Immunotherapies 3.16 Most Valuable R&D Projects in Cancer Immunotherapy
4.0 Challenges in Cancer Medicine Research: An Overview 4.1 Years of Failures and Emerging Successes in Melanoma Medicine Research 4.2 A New Era for Lung Cancer Medicines 4.3 Ray of Hope for Brain Cancer Patients
6.0 Available Immunotherapies for Cancer by Disease Type: An Overview 6.1 Melanoma Skin Cancer and Immunotherapy 6.2 Breast Cancer and Immunotherapy 6.3 Immunotherapy for Prostate Cancer 6.4 Immunotherapy for Lung Cancer 6.5 Immunotherapy for Colorectal Cancer 6.6 Immunotherapies in Development for Lymphoma 6.7 Immunotherapy for Kidney Cancer 6.8 Dominance of MAbs and Vaccines in Cancer Clinical Research 6.9 Oncology Biologics Losing Patent Protection
7.0 Cancer Incidence and Mortality: An Overview 7.1 Global Economic Burden of Cancer 7.2 Global Burden of Cancer 7.3 Top Five Most Frequent Cancers, Globally 7.4 Cancer Deaths in Women 7.5 Prevalence and Mortality for Cancer Types Addressed by Immunotherapy
8.0 Market Analysis 8.1 Global Oncology Market 8.2 Top Ten Companies in Oncology Drug Sales 8.3 Top Five Oncology Drugs 8.4 Global Oncology Therapeutics Market by Cancer Type
9.0 Market for Cancer Immunotherapy 9.1 Key Drivers 9.2 Global Market for Cancer Immunotherapeutics 9.3 Global Market for Cancer Immunotherapy by Product Class 9.4 Global Market for Immunotherapy Drugs by Cancer Type 9.5 Global Market for Monoclonal Antibodies for Cancer by Type 9.6 Global Market for Cancer Vaccines 9.7 Global Market for Non-Specific Cancer Immunotherapeutics 9.8 Market Values for Selected Forthcoming Cancer Immunotherapeutics
11.0 Cancer Immunotherapy Market Participants by Product Segment
12.0 CAR T Therapy 12.1 Challenges Relating to Chimeric Antigen Receptor T Cells in Immunotherapy
13.0 Regulations Pertaining to Immunotherapy Regulation in the USA 13.1 Center for Biologics Evaluation and Research (CBER)
14.0 Regulations for Immunotherapy in Japan 14.1 PMDA and Immunotherapy
15.0 European Regulation and Immunotherapeutics 15.1 Introduction 15.2 Challenges for Immunotherapy in EMEA 15.3 Challenges Relating to Biomarkers in Immunotherapy 15.4 Challenges Relating to Chimeric Antigen Receptor T Cells in Immunotherapy 15.5 Estimating Optimal Cut-Off Parameters 15.6 EU-Approved Immunotherapies in Melanoma 15.7 Key Contacts Within EMA for Immunotherapeutics
16.0 Manufacturing of Immunotherapies 16.1 Introduction 16.2 Generation of CAR-Modified T Cells 16.3 Manufacturing Devices and Instruments Required for Immunotherapy Production 16.4 Good Manufacturing Procedure (GMP) for Immunotherapy 16.5 Case Study Production of Lentivirus Induced Dendritic Cells under GMP Conditions 16.6 Quality Control 16.7 Regulatory Affairs 16.8 Key Challenges in Manufacturing